Abnormal baroreceptor-mediated vasopressin release as possible marker in early diagnosis of multiple system atrophy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 1, 2004, Pages 110-115

  Deguchi, K ^a   Sasaki, I ^a   Touge, T ^a   Tsukaguchi, M ^a   Takeuchi, H ^a   Kuriyama, S ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NORADRENALIN; VASOPRESSIN;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FUNCTION TEST; HEAD TILTING; HUMAN; NORADRENALIN BLOOD LEVEL; PRESSORECEPTOR; PRIORITY JOURNAL; SHY DRAGER SYNDROME; VASOPRESSIN RELEASE;

AGED; AUTONOMIC NERVOUS SYSTEM; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MEDULLA OBLONGATA; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PRESSORECEPTORS; VASOPRESSINS;

EID: 0347755532     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-8.
2. Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1988;57:1099-111.
3. Wenning GK, Ben Shlomo Y, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-45.
4. Gilman S, Little R, Johanns J, et al. Evolution of sporodic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000;55:527-32.
5. Mathias CJ, Bannister R. Investigation of autonomic disorders. In: Mathias CJ, Bannister R, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. New York: Oxford University Press, 1999:169-95.
6. Parikh SM, Diedrich A, Biaggioni I, et al. The nature of the autonomic dysfunction in multiple system atrophy. J Neurol Sci 2002;200:1-10.
7. Polinsky RJ. Neuropharmacological investigation of autonomic failure. In: Mathias CJ, Bannister R, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. New York: Oxford University Press, 1999:232-44.
8. Polinsky RJ, Kopin IJ, Ebert MH, et al. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 1981;31:1-7.
9. Ziegler MG, Lake CR, Kopin IJ. The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 1977;296:293-7.
10. 123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994;49:81-4.
11. 123I-meta- iodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-94.
12. Goldstein DS, Holmes C, Cannon RO, et al. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997;336:696-702.
13. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998;65:65-71.
14. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697-702.
15. Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using positron magnetic resonance spectroscopy. Ann Neurol 1995;37:204-10.
16. Brooks D. Neuroimaging and allied studies in autonomic failure syndromes. In: Mathias CJ, Bannister R, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. New York: Oxford University Press, 1999:317-20.
17. Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997;349:1877-81.
18. Thomaides TN, Chaudhuri KR, Maule S, et al. Growth hormone response to clonidine in central and peripheral primary autonomic failure. Lancet 1992;340:263-6.
19. Friess E, Kuempfel T, Winkelmann J, et al. Increased growth hormone response to apomorphine in Parkinson's disease compared with multiple system atrophy. Arch Neurol 2001;58:241-6.
20. Winkler AS, Landau S, Chaudhuri KR. Serum prolactin levels in Parkinson's disease and multiple system atrophy. Clin Auton Res 2002;12:393-8.
21. Kaufmann H, Oribe E, Miller M, et al. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992;42:590-3.
22. Winkler AS, Marsden J, Parton M, et al. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord 2001;16:233-9.
23. Benarroch EE. Central neurotransmitters and neuromodulators in cardiovascular regulation. In: Mathias CJ, Bannister R, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. New York: Oxford University Press, 1999:37-44.
24. Oppenheimer DR. Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980;46:393-404.
25. DiBona GF, Wilcox CS. The kidney and the sympathetic nervous system. In: Mathias CJ, Bannister R, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. New York: Oxford University Press, 1999:143-50.
26. Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension: etiologic and clinical implications. Am J Med 1983;74:265-71.
27. Robertson GL. The regulation of vasopressin function in health and disease. Recent Prog Horm Res 1976;33:333-85.
28. Kimber J, Mathias O, Lees AJ, et al. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain 2000;123:1422-30.
29. Kimber J, Watson L, Mathias CJ. Neuroendocrine responses to levodopa in multiple system atrophy (MSA). Mov Disord 1999;14:981-7.
30. Benarroch EE, Smithson IL, Low PA, et al. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol 1998;43:156-63.
31. Kato S, Oda M, Hayashi H, et al. Decrease of medullary catecholaminergic neurons in multiple system atrophy and Parkinson's disease and their preservation in amyotrophic lateral sclerosis. J Neurol Sci 1995;132:216-21.
32. Benarroch EE. New findings on the neuropathology of multiple system atrophy. Auton Neurosci 2002;96:59-62.
33. Ruggiero DA, Cravo SL, Ranago V, et al. Central control of circulation by the rostral ventrolateral reticular nucleus: anatomical substrates. Prog Brain Res 1989;81:49-79.
34. Spyer KM. Annual Review Prize Lecture. Central nervous mechanisms contributing to cardiovascular control. J Physiol 1994;474:1-19.
35. Matthews MR. Autonomic ganglia and preganglionic neurones in autonomic failure. In: Mathias CJ, Bannister R, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. New York: Oxford University Press, 1999:329-39.
36. Nussey SS, Hawthorn J, Page SR, et al. Responses of plasma oxytocin and arginine vasopressin to nausea induced by apomorphine and ipecacuanha. Clin Endocrinol 1988;28:297-304.
37. Raschind MA, Peskind ER, Veith RC, et al. Differential effects of aging on neuroendocrine responses to physostigmine in normal men. J Clin Endocrinol Metab 1990;70:1420-5.
38. Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation 2000;102:2898-906.
39. Senda Y, Koike Y, Oiso Y, et al. Plasma vasopressin responses to orthostasis and hypertonic saline infusion in progressive autonomic failure. Rinsho Shinkeigaku 1988;28:1282-9.
40. Baylis PH. Posterior pituitary function in health and disease. Clin Endocrinol Metab 1983;12:747-70.
41. Baylis PH, Heath DA. Influence of presyncope and postural change upon plasma arginine vasopressin concentration in hydrated and dehydrated man. Clin Endocrinol 1977;7:79-83.
42. Task Force on Syncope, European Society of Cardiology. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001;22:1256-306.
43. Puritz R, Lightman SL, Wilcox CS, et al. Blood pressure and vasopressin in progressive autonomic failure: response to postural stimulation, L-DOPA and naloxone. Brain 1983;106:503-11.
44. Williams TDM, Lightman SL, Bannister R. Vasopressin secretion in progressive autonomic failure: evidence for defective afferent cardiovascular pathways. J Neurol Neurosurg Psychiatry 1985;48:225-8.
45. Kimber J, Watson L, Mathias CJ. Abnormal suppression of arginine-vasopressin by clonidine in multiple system atrophy. Clin Auton Res 1999;9:271-4.
46. Malessa S, Hirsch EC, Cervera P, et al. Catecholominergic systems in the medulla oblongata in parkinsonian syndromes: a quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear polsy, and striatonigral degeneration. Neurology 1990;40:1739-43.
47. Norbiato G, Bevilacqua M, Righini V, et al. Altered vasopressin response to metoclopramide in multiple system atrophy: evidence of a cholinergic defect in the hypothalamus. Acta Neurol Scand 1992;85:299-303.
48. Niimi Y, Ieda T, Hirayama M, et al. Clinical and physiological characteristics of autonomic failure with Parkinson's disease. Clin Auton Res 1999;9:139-44.
49. Hasegawa Y, Matsuoka Y, Ieda T, et al. Effect of standing on blood pressure, plasma vasopressin and norepinephrine in Parkinson's disease. New Trends Clin Neuropharmacol 1994;8:133.
50. Benarroch EE, Schmeichel AM, Parisi JE. Involvement of the ventrolateral medulla in parkinsonism with autonomic failure. Neurology 2000;54:963-8.